Souhaitez-vous accéder aux communiqués récents ?

  This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. ...

Oslo, Norway, 11 February 2016: Photocure (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in cancer and dermatology, announces its results for the fourth quarter...

Photocure will present its fourth quarter and full year 2015 report on Thursday 11 February 2016 at Hotel Continental, Oslo, Norway. The presentation will begin at 08:30 (CET) and representatives...

Oslo, Norway, December  15, 2015: Photocure (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in cancer and dermatology, will present a company overview at DNB's...

Phase 2b results demonstrate a significant reduction in inflammatory lesions and a significant improvement in overall acne severity  Oslo, Norway, December 14, 2015: Photocure (OSE: PHO), a...

Oslo, Norway, December 3, 2015: Photocure (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in cancer and dermatology, today announces that new clinical data on...

Oslo, Norway, 29 October 2015: Photocure (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in cancer and dermatology, announces its results for the third quarter...

Photocure will present its third quarter 2015 report on Thursday 29 October 2015 at Hotel Continental, Oslo, Norway. The presentation will begin at 08:30 (CET) and representatives from the company...

Oslo, Norway, October 2, 2015: Photocure (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in cancer and dermatology, today announces that the first patient has...

Oslo, September 22, 2015 - Photocure (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in cancer and dermatology today announces that a new patent for Cevira has...